Search | Clinical Trials Finder

Conditions: Influenza, Human
Interventions: Investigational aQIVc, licensed QIVr, licensed aQIV; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 50 Years and older
Enrollment: 7,741 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 51
States / cities: Tempe, Arizona • Little Rock, Arkansas • Huntington Beach, California + 47 more

Conditions: Cytomegalovirus Infections
Interventions: MF-59, Placebo, CMV gB vaccine; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 17 Years · Female only
Enrollment: 409 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2013
U.S. locations: 5
States / cities: Cincinnati, Ohio • Nashville, Tennessee • Galveston, Texas + 1 more

Conditions: HIV Infections
Interventions: Sub C gp140 Vaccine, MF59C.1 Adjuvant; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Birmingham, Alabama • Nashville, Tennessee • Seattle, Washington

Conditions: Influenza, Community-acquired Pneumonia, Cardiovascular Events
Interventions: Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4); Biological
Lead sponsor: Kaiser Permanente; Other
Eligibility: 65 Years and older
Enrollment: 1,500,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Oakland, California

Conditions: Alzheimer's Disease
Interventions: CAD106, Placebo, Alum, MF59; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Up to 85 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Costa Mesa, California • Boulder, Colorado • Hollywood, Florida + 2 more

Conditions: Healthy
Interventions: IVX-121, IVX-241, Placebo, MF59®; Biological · Other
Lead sponsor: Icosavax, Inc.; Industry
Eligibility: 60 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Hollywood, Florida • Atlanta, Georgia • Omaha, Nebraska + 1 more

Conditions: Influenza, Human
Interventions: 3.75 ug Panblok H7, 7.5 ug Panblok H7, 15 ug Panblok H7, MF59, AS03; Biological
Lead sponsor: Biomedical Advanced Research and Development Authority; Federal
Eligibility: 18 Years to 49 Years
Enrollment: 366 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Lenexa, Kansas • Wichita, Kansas • Lexington, Kentucky + 1 more

Conditions: HIV Infections
Interventions: rgp120/HIV-1MN, rgp120/HIV-1 SF-2; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years to 60 Years
Enrollment: 296 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1997
U.S. locations: 7
States / cities: Birmingham, Alabama • St Louis, Missouri • Rochester, New York + 3 more

Conditions: Influenza
Interventions: Fluzone, Fluad; Biological
Lead sponsor: Yale University; Other
Eligibility: 21 Years and older
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Avian Influenza, Immunisation
Interventions: Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, MF59 adjuvant; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 47 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza
Interventions: MF59-eH1N1; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 3 Years to 8 Years
Enrollment: 1,357 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 34
States / cities: Downey, California • Madera, California • Paramount, California + 29 more

Conditions: Influenza, Human
Interventions: aQIV or aTIV, QIV or TIV; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 65 Years and older
Enrollment: 38,769 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 111
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 96 more

Conditions: Avian Influenza, Influenza Immunisation
Interventions: A/H7N9, AS03, Phosphate Buffered Saline (PBS) diluent; Biological · Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 70 Years
Enrollment: 304 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more

Conditions: Influenza
Interventions: Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_100%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_0%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_25%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_50%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_100%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_0%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_25%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_50%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_100%MF59; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 753 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza
Interventions: Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, MF59; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 64 Years
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Decatur, Georgia • Iowa City, Iowa • Cincinnati, Ohio + 1 more

Conditions: Influenza
Interventions: AS03, MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 64 Years
Enrollment: 980 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Baltimore, Maryland • St Louis, Missouri • Nashville, Tennessee + 2 more

Conditions: HIV Infections
Interventions: ALVAC-HIV (vCP2438), Bivalent subtype C gp120/MF59, Bivalent subtype C gp120/AS01(B), Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more

Conditions: Influenza
Interventions: MF59-eH1N1_f; Biological
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 2,719 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 20
States / cities: Miami, Florida • Lenexa, Kansas • Omaha, Nebraska + 16 more

Conditions: HIV Infections
Interventions: rgp120/HIV-1 SF-2; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 2
States / cities: Nashville, Tennessee • Seattle, Washington

Conditions: Influenza
Interventions: 3.75 µg H5N8 antigen plus full dose AS03A, 7.5 µg H5N8 antigen plus full dose AS03A, 15 µg H5N8 antigen plus full dose AS03A, 3.75 µg H5N8 antigen plus half dose AS03A, 7.5 µg H5N8 antigen plus half dose AS03A, 15 µg H5N8 antigen plus half dose AS03A, 3.75 µg H5N8 antigen plus MF59, 7.5 µg H5N8 antigen plus MF59, 15 µg H5N8 antigen plus MF59, 3.75 µg H5N1 antigen plus full dose AS03A, 7.5 µg H5N1 antigen plus full dose AS03A, 15 µg H5N1 antigen plus full dose AS03A, 3.75 µg H5N1 antigen plus MF59, 7.5 µg H5N1 antigen plus MF59, 15 µg H5N1 antigen plus MF59; Biological
Lead sponsor: Biomedical Advanced Research and Development Authority; Federal
Eligibility: 18 Years and older
Enrollment: 1,380 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 20
States / cities: Atlanta, Georgia • Savannah, Georgia • Oak Lawn, Illinois + 17 more

Conditions: HIV Infections
Interventions: Clade B gag DNA/PLG and env DNA/PLG Microparticles, Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2007
U.S. locations: 4
States / cities: St Louis, Missouri • Providence, Rhode Island • Nashville, Tennessee + 1 more

Conditions: HIV Infections
Interventions: rgp120/HIV-1 SF-2, MTP-PE/MF59; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 4
States / cities: St Louis, Missouri • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more

Conditions: Influenza
Interventions: MF59 adjuvanted trivalent subunit influenza vaccine (aTIV), Non-adjuvanted trivalent subunit influenza vaccine (TIV); Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 65 Years and older
Enrollment: 7,109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 21
States / cities: Phoenix, Arizona • DeLand, Florida • Jacksonville, Florida + 15 more

Conditions: HIV Infections, HIV Seronegativity
Interventions: MTP-PE/MF59, Env 2-3; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1992
U.S. locations: 3
States / cities: Rochester, New York • Nashville, Tennessee • Seattle, Washington

Search by objective public record fields.

The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females

Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients

Safety and Immunogenicity of IVX-A12 in Healthy Older Adults

Panblok H7 Vaccine Adjuvanted With AS03 or MF59

A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults

Systems Investigation of Vaccine Responses in Aging and Frailty

A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

2017 A/H7N9 IIV Revaccination

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

H7N9 Mix and Match With MF59 in Healthy Adults

H7N9 Mix and Match With AS03 and MF59 in Healthy Adults

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months

Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59

Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults

Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant

Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects

A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59